MONTREAL, April 29, 2026
Pharmascience Canada has announced the official launch of ᴾʳpms-DOLUTEGRAVIR (dolutegravir tablets), marking an important milestone in expanding access to high-quality and affordable HIV treatment options across Canada. As the only Canadian generic manufacturer to receive Health Canada authorization for this product, Pharmascience is strengthening its leadership in the generic pharmaceutical market while supporting long-term healthcare sustainability and improved patient access to essential medicines.
Strengthening Access to HIV Treatment in Canada
The launch of pms-DOLUTEGRAVIR represents a significant advancement in Canada’s pharmaceutical landscape, particularly for patients requiring reliable access to antiretroviral therapy. Dolutegravir is a widely used treatment option in HIV care, recognized for its effectiveness in managing viral suppression and supporting long-term treatment outcomes. By introducing a Canadian-made generic version, Pharmascience is helping reduce treatment costs while ensuring a stable domestic supply of an essential medicine.
According to Mike Dutton, Vice President and General Manager of Pharmascience Canada, this launch reflects the company’s continued commitment to improving healthcare accessibility while strengthening its portfolio in critical therapeutic areas. He emphasized that being the only Canadian generic manufacturer approved for this product demonstrates Pharmascience’s dedication to delivering medicines that make Canada’s healthcare system more sustainable and patient-focused.
Expanding Leadership in Canadian Pharmaceutical Manufacturing
Advertisement
Founded in 1983, Pharmascience Inc. has grown into the largest pharmaceutical employer in Quebec, with more than 1,600 employees based in Montreal. The company is recognized as one of Canada’s leading drug manufacturers and operates as a fully integrated private pharmaceutical company with strong domestic roots and an expanding international presence.
Today, Pharmascience distributes products in over 50 countries, reinforcing its position as both a national healthcare contributor and a global pharmaceutical supplier. Its continued investment in high-demand therapeutic areas such as infectious diseases, cardiovascular care, and specialty generics reflects a long-term strategy centered on innovation, accessibility, and global expansion.
The launch of pms-DOLUTEGRAVIR further enhances Pharmascience’s generic medicine portfolio and supports Canada’s goal of strengthening domestic pharmaceutical production capacity while reducing dependency on international supply chains.
Strong R&D Investment and Workplace Excellence
Pharmascience continues to invest heavily in research and development, ranking 41st among Canada’s top 100 investors in R&D in 2025, with annual investments totaling approximately $55 million. This strong commitment to innovation allows the company to accelerate product development, regulatory approvals, and expanded treatment access across multiple therapeutic categories.
In addition to scientific growth, the company places major emphasis on employee development and workplace culture. Through various youth initiatives, training programs, and leadership development efforts, Pharmascience supports both personal and professional advancement across its workforce. In 2026, the company was certified as a Great Place to Work for the fifth consecutive year, reflecting its strong reputation as a leading employer in the Canadian life sciences sector.
With the successful launch of pms-DOLUTEGRAVIR, Pharmascience reinforces its position as a key driver of affordable healthcare innovation in Canada. By combining regulatory excellence, domestic manufacturing strength, and long-term investment in people and science, the company continues to play a major role in improving access to life-saving medicines for patients across the country.
Source: Pharmascience press release
